

U.S. PATENT & TRADEMARK OFFICE
MAY 05 2003
SEARCHED
INDEXED
FILED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Durham et al.	Group Art Unit: 1646
Serial No.: 09/826,290	Examiner: O. Chernyshev
Filing Date: 04/03/2001	Attorney Docket No.: POA-002.01
For: <i>Nucleic Acid Molecules, Polypeptides and Uses Therefor, Including Diagnosis and Treatment of Alzheimer's Disease</i>	

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date set forth below.

APRIL 28, 2003 By: Kerry Richard
Date of Signature and Mail Deposit KERRY RICHARD

DECLARATION OF HOLLY D. SOARES UNDER 37 CFR 1.132

Dear Madam:

I, Holly D. Soares, do hereby declare as follows:

1. I am presently a Senior Research Investigator at Pfizer Central Research and Development, on Eastern Point Road in Groton, CT. Concurrently, I am an Adjunct Assistant Professor in the Department of Anatomy and Neurobiology at Morehouse School of Medicine in Atlanta, Georgia.
2. I am actively involved in research examining the molecular mechanisms and biomarkers of Alzheimer's disease.
3. The attached Exhibit B, presents data further documenting the association between the level of API-6 in a biological sample of a subject, represented by sequences: LSPYVNYNSFR, AETYEGVYQCTAR, GKPPPSFSWTR, and IDGDTIIFSNVQER, and Alzheimer's disease. API-6 is a fragment of the protein NCAM (neuronal cell adhesion molecule). Specifically, the data presented demonstrates that a decrease in the level of API-6 in the CSF fluid of an Alzheimer's patient, Subject A, is associated with a concomitant decrease in cognitive ability, a clinical marker of Alzheimer's disease. As demonstrated in Panel B, no decrease in the level of API-6 is observed in control subjects.

BEST AVAILABLE COPY

over time. Patients were tracked longitudinally over 3-8 years. Cerebrospinal fluid was taken periodically and analyzed for NCAM levels by 2D gel electrophoresis.

5. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

March 26, 2003
Date

Holly D. Soares
Holly Soares, Ph.D.

BEST AVAILABLE COPY